Equity Details
Price & Market Data
Price: $1.95
Daily Change: -$0.084 / 4.32%
Daily Range: $1.91 - $2.04
Market Cap: $253,502,656
Daily Volume: 592,495
Performance Metrics
1 Week: -0.52%
1 Month: 12.28%
3 Months: 20.00%
6 Months: 28.00%
1 Year: -12.33%
YTD: -6.34%
About Inhibikase Therapeutics, Inc. (IKT)
Access updated market data for Inhibikase Therapeutics, Inc. (IKT). Current price: 1.95, daily change: -$0.084 / 4.32%. Market cap: 253,502,656. Performance over 1-week, 1-month, and 3-month.
Company Details
Employees: 35
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.